ACTRN12622000750785招募中未知
Patient-Reported Outcomes to Evaluate Three Pharmaceutical Grade Medicinal Cannabis Oils in Patients with Chronic Pain of Musculoskeletal Origin
evin Health Limited0 个研究点目标入组 100 人开始时间: 2022年5月25日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •Aged over 18 years
- •A diagnosis of treatment resistant chronic pain of musculoskeletal origin
- •Ability to give informed consent
- •Willing and able to follow study instructions and likely to complete all PROM requirements via study website
- •Able to provide informed consent
- •Have a life-expectancy of >3 months
- •Understand that there is a risk of prosecution if driving a car while under treatment
- •Patient has been identified as eligible to receive medicinal cannabis under the TGA Special Access Scheme/Authorised by the Principal Investigator for chronic pain
- •Participants must have been lawfully prescribed Levin Balance, Levin CBD+ or Levin THC+ by the Principal Investigator
- •Participants agree to abstain from using another cannabis product other than their Levin Health product for the duration of their enrolment in the study
排除标准
- •have cognitive impairment
- •are pregnant
- •are unable to speak, read and/or write in English
- •are unable to provide informed consent
- •are unable to provide an email address
- •have received prescription medicinal cannabis within the last 4 weeks
- •are using illicit cannabis
研究者
相似试验
进行中（未招募）
不适用
An Evaluation of Patient Reported Outcomes and Ocular Surface Health in Patients Using DuoTrav APS Eye Drops Solution Versus XALACOM® Eye Drops Solution - DuoTrav APS versus XALACOM® in Patient Reported Outcomes and Ocular Surface HealthEUCTR2009-010604-29-BEAlcon Research, Ltd.400
已完成
3 期
An Evaluation of Patient Reported Outcomes and Ocular Surface Health in Patients Using DuoTrav APS Eye Drops Solution Versus XALACOM® Eye Drops Solution.raised intra-ocular pressure with optic nerve damageraised intra-ocular pressure without optic nerve damage10018307NL-OMON35130Alcon Laboratories30
进行中（未招募）
不适用
An Evaluation of Patient Reported Outcomes and Ocular Surface Health in Patients Using Travoprost APS Eye Drops Solution Versus XALATAN Eye Drops Solution - Travoprost APS versus XALATAN in OSDIOpen Angle Glaucoma or Ocular HypertensionMedDRA version: 9.1Level: LLTClassification code 10030043Term: Ocular hypertensionMedDRA version: 9.1Level: LLTClassification code 10030348Term: Open angle glaucomaEUCTR2009-010606-10-GBAlcon Research, Ltd.516
进行中（未招募）
不适用
An Evaluation of Patient Reported Outcomes and Ocular Surface Health in Patients Using DuoTrav APS Eye Drops Solution Versus XALACOM® Eye Drops Solution - DuoTrav APS versus XALACOM® in Patient Reported Outcomes and Ocular Surface Healthglaucoma/dry eyeMedDRA version: 9.1Level: LLTClassification code 10030348Term: Open angle glaucomaMedDRA version: 9.1Level: HLGTClassification code 10018307Term: Glaucoma and ocular hypertensionMedDRA version: 9.1Level: LLTClassification code 10030043Term: Ocular hypertensionMedDRA version: 9.1Level: LLTClassification code 10013774Term: Dry eyeEUCTR2009-010604-29-PTAlcon Research, Ltd.400
进行中（未招募）
不适用
An Evaluation of Patient Reported Outcomes and Ocular Surface Health in Patients Using Travoprost APS Eye Drops Solution Versus XALATAN Eye Drops Solution - Travoprost APS versus XALATAN® in Patient Reported Outcomes and Ocular Surface HealthEUCTR2009-010606-10-LTAlcon Research, Ltd.516